


M13 Reverse priming site Mlu I  
 201 CACA CAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTAT TTAGGTGACG CGTTAGAATA  
 GTGT GTCCCTT TGTCGATACT GGTACTAATG CGGTTTCGATA AATCCACTGC GCAATCTTAT  
  
Nsi I Hind III Kpn I Sac I BamH I Spe I  
 CTC AAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT  
 GAGTTCGATA CGTAGTTCGA ACCATGGCTC GAGCCTAGGT GATCATTTGCC GGCGGTCACA  
  
EcoR I EcoR I Pst I EcoR V  
 GCTGGAATTC AGG **Blunt PCR Product** CCTGAATTCT GCAGATA  
 CGACCTTAAG TCC GACTTAAGA CGTCTAT  
  
Not I Xho I Nsi I Xba I Apa I T7 promoter/priming site  
 TCCATCACAC TGGCGGCCGC TCGAGCATGC ATCTAGAGGG CCCAATTTCG CCTATAGTGA  
 AGGTAGTGTG ACCGCCGGCG AGCTCGTACG TAGATCTCCC GGGTTAAGCG GGATATCACT  
  
M13 Forward (-20) priming site  
 GTCGATTAC AATTCACTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT 470  
 CAGCATAATG TTAAGTGACC GGCAGCAAAA TGTTCAGCA CTGACCCTTT TGGGACCGCA



**Comments for pCR<sup>®</sup>-Blunt**  
**3512 nucleotides**

*Lac* promoter/operator region: bases 95-216  
 M13 Reverse priming site: bases 205-221  
*LacZ*-alpha ORF: bases 217-570  
 T7 promoter priming site: bases 400-419  
 M13 Forward (-20) priming site: bases 427-442  
 Fusion joint: bases 571-579  
*ccdB* lethal gene ORF: bases 580-882  
 Kanamycin resistance ORF: bases 1231-2025  
 Zeocin resistance ORF: bases 2231-2605  
 pUC origin: bases 2673-3386